CADL: Candel Therapeutics Inc. Analyst Consensus Forecast

Symbol and logo of brand Candel (CADL)

Candel Therapeutics (CADL) is developing viral tumor therapies, relying on long-term treatment courses to ensure stable revenue. The company is implementing ESG standards by reducing laboratory waste and adhering to bioethics. Anticipation of the new vaccine test results at the current price of 22.13 confirms the price action chart on GURU.Markets, which has already priced in clinical stage risks.

CADL (Candel Therapeutics, Inc.) Price Target Chart history from 07/04/2022 to 11/12/2026

Analytical breakdowns for Candel Therapeutics (CADL)

- market price and analyst price targets:
Stock Quotes candeltx.com|CADL - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Candel|CADL - Enterprise Value
- balance sheet equity data:
Equity per Share Candel Therapeutics|CADL - Company Book Value|Market Value to Book Value Ratio candeltx.com|CADL - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Candel Therapeutics|CADL - Long-Term Debt to Capital|Short-Term Debt to Capital candeltx.com|CADL - Company Debts|Debt to Book Value Ratio Candel|CADL - Company Long-Term Debts|Company Current Liabilities Candel Therapeutics|Immediate Liquidity candeltx.com
- net income and valuation multiples indicators:
CADL - Company Net Income|Expected Net Income Candel Therapeutics|CADL - Price to Earnings Ratio|Future Price to Earnings Multiple candeltx.com|CADL - PEG Multiple|Enterprise Value to EBITDA Ratio Candel|CADL - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Candel Therapeutics|CADL - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months candeltx.com|CADL - Earnings growth in current year|Expected net earnings per share growth next year Candel Therapeutics
Fundamental company analysis:Candel Therapeutics Inc. (CADL)
Original product of Candel Therapeutics

The lack of revenue and high capital burn rate associated with the development of oncolytic vaccines at Candel Therapeutics (CADL) make the stock price extremely sensitive to clinical trial results. The history of expert consensus estimates reflects a weighted average target price calculated by investment banks via discounted cash flow analysis, where any sharp fluctuations in the curve signal a revision of the market's fundamental expectations regarding the success of the drugs.

Competing companies

Consensus Target beigene.com ONC|Analyst Consensus Forecast HALO (Halozyme)|Analyst Consensus Forecast Revolution Medicines Inc RVMD|Ascentage - Analyst Consensus Forecast|CGON (CG Oncology Therapeutics) - Broker Consensus Forecast|UroGen Pharma Ltd. (URGN) - Price Target Chart|BCAX (bicara.com) - Price Target Chart|PSNL (Personalis) - Analyst Consensus Forecast|Consensus Target Erasca Inc (ERAS)|Analyst Consensus Forecast DCTH|Analyst Consensus Forecast Y-mAbs Corp (YMAB)|Price Target Chart Aura Biosciences, Inc. AURA|ARAY: Broker Consensus Forecast|SELLAS Life Sciences Group Inc. - Analyst Consensus Forecast|Actuate Therapeutics Inc. (ACTU) - Consensus Target|CTOR: Analyst Consensus Forecast|Average Forecast Price TuHURA Biosciences (HURA)|Price Target Chart Protara Therapeutics|FATE: Fair Value Consensus|Consensus Target WHWK (Aadi Bioscience Inc)|TCRX (tscan.com) - Fair Value Consensus|Analyst Consensus Forecast CSBR (Champions Oncology, Inc.)|XBIT - Consensus Target|CVM: Consensus Target|OSTX - Analyst Consensus Forecast|Radiopharm Theranostics Limited (RADX) - Price Target Chart|Artiva Biotherapeutics - Fair Value Consensus|ANL (Adlai Nortye Ltd) - Analyst Consensus Forecast|Average Forecast Price Veru Corporation VERU|Analyst Consensus Forecast TPST|Consensus Target xiliotx.com XLO|Analyst Consensus Forecast RENB (Renovaro)|Analyst Consensus Forecast Mural Oncology PLC MURA|KAPA - Price Target Chart|OKUR (OnKure Therapeutics Inc) - Broker Consensus Forecast|GDTC: Analyst Consensus Forecast|Broker Consensus Forecast CRIS|APLM (Apollomics Inc.) - Analyst Consensus Forecast|Average Forecast Price Tharimmune Inc THAR|Price Target Chart Advanced Biomed Inc (ADVB)|Price Target Chart GNPX (Genprex Inc)|Calidi Biotherapeutics, Inc. - Consensus Target|Fair Value Consensus SBFM|XBIO: Consensus Target|Salarius Pharmaceuticals Inc - Analyst Forecast Prices|PPBT: Analyst Consensus Forecast|American Oncology Network, Inc. - Fair Value Consensus|BGNE (BeiGene, Ltd.) - Analyst Consensus Forecast|Average Forecast Price checkpointtx.com CKPT|Price Target Chart Elevation Oncology, Inc. (ELEV)|ICAD (icadmed.com) - Fair Value Consensus|Analyst Consensus Forecast IKNA (Ikena Oncology)|Analyst Consensus Forecast Notable Labs Corp NTBL|VIRX - Price Target Chart|Forecast Levels Chart MOR|NAYA: Analyst Consensus Forecast|Average Forecast Price Ascentage Pharma Group International (AAPGV)